Servier shared a post on X:
“We’re thrilled to announce a licensing agreement for a promising treatment for Uveal Melanoma, a rare and aggressive eye cancer, developed by IDEAYA Biosciences.
Uveal melanoma is a rare and aggressive form of eye cancer that originates in the uveal tract, which includes the iris, ciliary body, and choroid.
At Servier, oncology is a top innovation priority — close to 70% of our R&D budget is dedicated to advancing treatments for rare cancers.
Read more in our press release.”
More Posts Featuring Servier.
